Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
RDIV vs SCHD: Two Distinct Paths to Dividend Income

RDIV vs SCHD: Two Distinct Paths to Dividend Income

Key Takeaways

  • RDIV and SCHD both target high-dividend U.S. equities, but they pursue that goal through sharply different methodologies: revenue weighting versus quality screening.
  • RDIV holds roughly 60 concentrated, high-yield names tilted toward financials, energy, and consumer staples, with a 0.39% expense ratio.
  • SCHD holds about 100 stocks selected for dividend durability and financial strength, with a much lower 0.06% expense ratio.
  • Cost and diversification are the decisive gaps: SCHD is materially cheaper and more broadly diversified, while RDIV carries more cyclical and single-name risk.
  • Tickeron AI Verdict: SCHD is the favored ticker, reflecting superior cost efficiency, quality screens, and more consistent risk-adjusted positioning.

Introduction

Income-seeking investors often compare RDIV and SCHD because both sit in the large-cap value and dividend segment of the U.S. equity market. Yet they are not direct substitutes. SCHD emphasizes dividend quality, stability, and long-term growth, while RDIV prioritizes raw dividend yield through a revenue-weighted framework. This ETF comparison matters now because the ongoing rotation between growth and value, shifting interest-rate expectations, and renewed demand for income have brought both funds into focus. When I reviewed the latest holdings data, I also checked this using Tickeron’s AI Screener to see how the two line up against peers. Understanding the structural differences between these strategies—rather than short-term price moves—is essential for any investor evaluating sector exposure and relative positioning in an income portfolio.

A Closer Look at RDIV

RDIV tracks the S&P 900 Dividend Revenue-Weighted Index, a rules-based benchmark that starts with the S&P 900, removes the highest-yielding 5% of names and the top 5% of payers within each sector, then selects the 60 highest-yielding stocks and weights them by total revenue. This produces a concentrated, non-diversified portfolio of roughly 60 to 61 holdings that is reconstituted and rebalanced quarterly.

The fund's sector allocation skews toward cyclical and defensive income names, led by consumer staples, financials, communication services, energy, and real estate, with a modest weight in healthcare and little to no technology exposure. Representative top holdings include Comcast, Prudential Financial, PepsiCo, Ford Motor, Bristol-Myers Squibb, AT&T, ONEOK, and Chevron. The net expense ratio is 0.39%, and the fund's revenue-weighting approach gives it a large-cap value orientation with a forward P/E ratio well below the broad market. Its elevated yield comes with meaningful single-stock and cyclical concentration risk.

Understanding SCHD

SCHD tracks the Dow Jones U.S. Dividend 100 Index, which selects roughly 100 U.S. companies that have paid dividends for at least 10 consecutive years and screens them on metrics such as cash flow to total debt, return on equity, dividend yield, and five-year dividend growth. The result is a quality-oriented, diversified portfolio of about 100 to 104 holdings that is reviewed quarterly and reconstituted annually.

Sector exposure is anchored in energy, consumer staples, healthcare, and industrials, with additional weight in financials, information technology, and consumer discretionary. Top holdings have included Merck, Abbott Laboratories, Amgen, Coca-Cola, Home Depot, Verizon Communications, ConocoPhillips, Chevron, UnitedHealth Group, and Procter & Gamble. The fund charges a 0.06% expense ratio and carries a lower beta than RDIV, reflecting a defensive, large-cap value profile built around financially durable dividend payers rather than the highest-yielding names.

Industry and Thematic Backdrop

Both funds operate at the intersection of income investing and the value trade, and both are sensitive to the macro backdrop. Rising bond yields can pressure dividend equities by offering competing risk-free income, while falling yields tend to revive demand for yield-bearing stocks. The two portfolios also carry notable energy, financial, and healthcare exposure, so commodity prices, credit conditions, and pharmaceutical earnings cycles all influence fund performance. RDIV's heavier financials and energy tilt makes it more sensitive to rate and oil price swings, while SCHD's staples and healthcare emphasis gives it a more defensive character. Regulatory and policy developments affecting banks, energy producers, and drugmakers remain key swing factors for both strategies in recent market cycles.

Performance and Positioning Comparison

Over recent market cycles, SCHD has generally delivered steadier relative positioning thanks to its quality filters and lower volatility, while RDIV has shown sharper swings tied to value and cyclical rotations. RDIV's concentrated, yield-first approach can outperform during strong value or energy rallies, but its higher expense ratio and single-stock concentration have weighed on longer-horizon risk-adjusted returns. SCHD's diversified, lower-cost structure and emphasis on dividend growth have supported more consistent compounding, albeit with a slightly lower headline yield. Investors weighing fund performance should note that RDIV offers a higher distribution yield but at the cost of greater cyclicality, while SCHD prioritizes dividend durability and total-return resilience across economic conditions.

Enhancing Research with Tickeron Tools

In my own workflow, Tickeron’s AI Screener has become a useful way to quickly compare dividend ETFs like these on fundamentals, holdings overlap, and risk metrics. It surfaces patterns across thousands of names without requiring hours of manual data pulls, helping me stay focused on the structural differences that matter most for long-term allocation decisions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SCHD, RDIV

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


SCHD's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for SCHD moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 instances where the indicator moved out of the overbought zone. In 34 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 64 cases where SCHD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCHD as a result. In 61 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for SCHD turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

SCHD broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

SCHD moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SCHD crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 84%.

Following a +1.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHD advanced for three days, in 265 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 282 of 364 cases where SCHD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Notable companies

The most notable companies in this group are Chevron Corp (NYSE:CVX), Coca-Cola Company (NYSE:KO), Procter & Gamble Company (NYSE:PG), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Home Depot (NYSE:HD), Texas Instruments (NASDAQ:TXN), Amgen (NASDAQ:AMGN), PepsiCo (NASDAQ:PEP), Abbott Laboratories (NYSE:ABT).

Industry description

The investment seeks to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100™ Index. To pursue its goal, the fund generally invests in stocks that are included in the index. The index is designed to measure the performance of high dividend yielding stocks issued by U.S. companies that have a record of consistently paying dividends, selected for fundamental strength relative to their peers, based on financial ratios. The fund will invest at least 90% of its net assets in these stocks.

Market Cap

The average market capitalization across the Schwab US Dividend Equity ETF (SCHD) ETF is 57.94B. The market cap for tickers in the group ranges from 363.12M to 417.06B. CVX holds the highest valuation in this group at 417.06B. The lowest valued company is AMSF at 363.12M.

High and low price notable news

The average weekly price growth across all stocks in the Schwab US Dividend Equity ETF (SCHD) ETF was 13%. For the same ETF, the average monthly price growth was 33%, and the average quarterly price growth was 132%. WEN experienced the highest price growth at 4%, while FLO experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Schwab US Dividend Equity ETF (SCHD) ETF was 15%. For the same stocks of the ETF, the average monthly volume growth was -14% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 42
Price Growth Rating: 44
SMR Rating: 42
Profit Risk Rating: 58
Seasonality Score: 10 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.